• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

I324M 缺失功能突变的精氨酸血管加压素受体 2 对 X 连锁性肾性尿崩症的功能特征分析。

Functional characterization of a loss-of-function mutant I324M of arginine vasopressin receptor 2 in X-linked nephrogenic diabetes insipidus.

机构信息

Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, 300052, China.

出版信息

Sci Rep. 2021 May 26;11(1):11057. doi: 10.1038/s41598-021-90736-z.

DOI:10.1038/s41598-021-90736-z
PMID:34040143
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8154955/
Abstract

X-linked nephrogenic diabetes insipidus (X-linked NDI) is a rare inherited disease mainly caused by lost-of-function mutations in human AVPR2 gene encoding arginine vasopressin receptor 2 (V2R). Our focus of the current study is on exploration of the functional and biochemical properties of Ile324Met (I324M) mutation identified in a pedigree showing as typical recessive X-linked NDI. We demonstrated that I324M mutation interfered with the conformation of complex glycosylation of V2R. Moreover, almost all of the I324M-V2R failed to express on the cell surface due to being captured by the endoplasmic reticulum control system. We further examined the signaling activity of DDAVP-medicated cAMP and ERK1/2 pathways and the results revealed that the mutant receptor lost the ability in response to DDAVP stimulation contributed to the failure of accumulation of cAMP and phosphorylated ERK1/2. Based on the characteristics of molecular defects of I324M mutant, we selected two reagents (SR49059 and alvespimycin) to determine whether the functions of I324M-V2R can be restored and we found that both compounds can significantly "rescue" I324M mutation. Our findings may provide further insights for understanding the pathogenic mechanism of AVPR2 gene mutations and may offer some implications on development of promising treatments for patients with X-linked NDI.

摘要

X 连锁遗传性尿崩症(X-linked NDI)是一种罕见的遗传性疾病,主要由编码精氨酸加压素受体 2(V2R)的人 AVPR2 基因突变引起。本研究的重点是探索在一个表现为典型隐性 X 连锁 NDI 的家系中发现的 Ile324Met(I324M)突变的功能和生化特性。我们证明了 I324M 突变干扰了 V2R 复杂糖基化的构象。此外,由于被内质网控制系统捕获,几乎所有的 I324M-V2R 都无法在细胞表面表达。我们进一步检查了 DDAVP 介导的 cAMP 和 ERK1/2 通路的信号转导活性,结果表明突变受体丧失了对 DDAVP 刺激的反应能力,导致 cAMP 和磷酸化 ERK1/2 的积累失败。基于 I324M 突变的分子缺陷特征,我们选择了两种试剂(SR49059 和 alvespimycin)来确定 I324M-V2R 的功能是否可以恢复,我们发现这两种化合物都可以显著“挽救”I324M 突变。我们的发现可能为理解 AVPR2 基因突变的致病机制提供进一步的见解,并可能对开发治疗 X 连锁遗传性尿崩症患者的有前途的治疗方法提供一些启示。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4c0/8154955/2c1bf2af93c9/41598_2021_90736_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4c0/8154955/90d00582d231/41598_2021_90736_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4c0/8154955/9f854d0537dc/41598_2021_90736_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4c0/8154955/6abc7b19ea28/41598_2021_90736_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4c0/8154955/4524171cb348/41598_2021_90736_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4c0/8154955/b9d209def8e4/41598_2021_90736_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4c0/8154955/2c1bf2af93c9/41598_2021_90736_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4c0/8154955/90d00582d231/41598_2021_90736_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4c0/8154955/9f854d0537dc/41598_2021_90736_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4c0/8154955/6abc7b19ea28/41598_2021_90736_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4c0/8154955/4524171cb348/41598_2021_90736_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4c0/8154955/b9d209def8e4/41598_2021_90736_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4c0/8154955/2c1bf2af93c9/41598_2021_90736_Fig6_HTML.jpg

相似文献

1
Functional characterization of a loss-of-function mutant I324M of arginine vasopressin receptor 2 in X-linked nephrogenic diabetes insipidus.I324M 缺失功能突变的精氨酸血管加压素受体 2 对 X 连锁性肾性尿崩症的功能特征分析。
Sci Rep. 2021 May 26;11(1):11057. doi: 10.1038/s41598-021-90736-z.
2
Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus.一种导致肾性尿崩症的新型血管加压素-2受体突变的鉴定、特征描述及挽救
Clin Endocrinol (Oxf). 2009 Sep;71(3):388-93. doi: 10.1111/j.1365-2265.2008.03513.x. Epub 2008 Dec 18.
3
A novel AVPR2 splice site mutation leads to partial X-linked nephrogenic diabetes insipidus in two brothers.一种新的AVPR2剪接位点突变导致两兄弟患部分性X连锁肾性尿崩症。
Eur J Pediatr. 2016 May;175(5):727-33. doi: 10.1007/s00431-015-2684-4. Epub 2016 Jan 21.
4
Altered agonist sensitivity of a mutant v2 receptor suggests a novel therapeutic strategy for nephrogenic diabetes insipidus.突变型血管加压素2受体激动剂敏感性的改变提示了一种治疗肾性尿崩症的新策略。
Mol Endocrinol. 2014 May;28(5):634-43. doi: 10.1210/me.2013-1424. Epub 2014 Mar 14.
5
Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model.在极化细胞模型中对肾性尿崩症中血管加压素V2受体突变体的表征。
Am J Physiol Renal Physiol. 2005 Aug;289(2):F265-72. doi: 10.1152/ajprenal.00404.2004.
6
Characterization of three vasopressin receptor 2 variants: an apparent polymorphism (V266A) and two loss-of-function mutations (R181C and M311V).鉴定三种血管升压素受体 2 变体:一种明显的多态性(V266A)和两种失活突变(R181C 和 M311V)。
PLoS One. 2013 Jun 6;8(6):e65885. doi: 10.1371/journal.pone.0065885. Print 2013.
7
Vasopressin type 2 receptor V88M mutation: molecular basis of partial and complete nephrogenic diabetes insipidus.血管加压素 2 型受体 V88M 突变:部分和完全肾性尿崩症的分子基础。
Nephron Physiol. 2010;114(1):p1-10. doi: 10.1159/000245059. Epub 2009 Oct 8.
8
A case of a novel mutant vasopressin receptor-dependent nephrogenic diabetes insipidus with bilateral non-obstructive hydronephrosis in a middle aged man: differentiation from aquaporin-dependent nephrogenic diabetes insipidus by response of factor VII and von Willebrand factor to 1-diamino-8-arginine vasopressin administration.一名中年男性患新型突变型血管加压素受体依赖性肾性尿崩症伴双侧非梗阻性肾积水的病例:通过因子VII和血管性血友病因子对1-二氨基-8-精氨酸血管加压素给药的反应与水通道蛋白依赖性肾性尿崩症相鉴别
Endocr J. 2003 Dec;50(6):809-14. doi: 10.1507/endocrj.50.809.
9
Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments.血管加压素 2 型受体替换(R137H/C/L)导致的肾性尿崩症和抗利尿激素不适当分泌综合征的功能特征:对治疗的影响。
Mol Pharmacol. 2010 May;77(5):836-45. doi: 10.1124/mol.109.061804. Epub 2010 Feb 16.
10
Identification and characterization of a novel X-linked AVPR2 mutation causing partial nephrogenic diabetes insipidus: a case report and review of the literature.鉴定并描述一个导致部分性肾性尿崩症的新型 X 连锁 AVP2R 基因突变:病例报告及文献复习。
Metabolism. 2012 Jul;61(7):922-30. doi: 10.1016/j.metabol.2012.01.005. Epub 2012 Mar 3.

本文引用的文献

1
Characterization of five novel vasopressin V2 receptor mutants causing nephrogenic diabetes insipidus reveals a role of tolvaptan for M272R-V2R mutation.鉴定五种导致肾性尿崩症的新型血管加压素 V2 受体突变体,揭示托伐普坦治疗 M272R-V2R 突变的作用。
Sci Rep. 2020 Oct 2;10(1):16383. doi: 10.1038/s41598-020-73089-x.
2
AQP2: Mutations Associated with Congenital Nephrogenic Diabetes Insipidus and Regulation by Post-Translational Modifications and Protein-Protein Interactions.AQP2:与先天性肾性尿崩症相关的突变及翻译后修饰和蛋白-蛋白相互作用的调节。
Cells. 2020 Sep 26;9(10):2172. doi: 10.3390/cells9102172.
3
Diabetes Insipidus: An Update.
尿崩症:最新进展。
Endocrinol Metab Clin North Am. 2020 Sep;49(3):517-531. doi: 10.1016/j.ecl.2020.05.012. Epub 2020 Jul 15.
4
GENETICS IN ENDOCRINOLOGY Pathophysiology, diagnosis and treatment of familial nephrogenic diabetes insipidus.内分泌遗传学 家族性肾性尿崩症的病理生理学、诊断和治疗。
Eur J Endocrinol. 2020 Aug;183(2):R29-R40. doi: 10.1530/EJE-20-0114.
5
V2 vasopressin receptor mutations.V2 血管加压素受体突变。
Vitam Horm. 2020;113:79-99. doi: 10.1016/bs.vh.2019.08.012. Epub 2019 Sep 13.
6
Evaluation of pharmacochaperone-mediated rescue of mutant V2 receptor proteins.评价药物伴侣介导的突变 V2 受体蛋白的拯救。
Eur J Pharmacol. 2019 Dec 15;865:172803. doi: 10.1016/j.ejphar.2019.172803. Epub 2019 Nov 15.
7
Diabetes insipidus.尿崩症。
Nat Rev Dis Primers. 2019 Aug 8;5(1):54. doi: 10.1038/s41572-019-0103-2.
8
Activation of AQP2 water channels without vasopressin: therapeutic strategies for congenital nephrogenic diabetes insipidus.无血管加压素时水通道蛋白2(AQP2)水通道的激活:先天性肾性尿崩症的治疗策略
Clin Exp Nephrol. 2018 Jun;22(3):501-507. doi: 10.1007/s10157-018-1544-8. Epub 2018 Feb 24.
9
Hereditary Nephrogenic Diabetes Insipidus: Pathophysiology and Possible Treatment. An Update.遗传性肾性尿崩症:病理生理学和可能的治疗。更新。
Int J Mol Sci. 2017 Nov 10;18(11):2385. doi: 10.3390/ijms18112385.
10
Hyponatremia and V2 vasopressin receptor upregulation: a result of HSP90 inhibition.低钠血症与V2血管加压素受体上调:HSP90抑制的结果
Cancer Chemother Pharmacol. 2017 Oct;80(4):673-684. doi: 10.1007/s00280-017-3390-x. Epub 2017 Aug 4.